Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2021
NICE backs NHS use of Lilly’s Olumiant in eczema
3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis ...
Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...
Posted by Michael Wonder on 25 Feb 2021
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
Posted by Michael Wonder on 25 Feb 2021
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria
25 February 2021 - NICE has today issued draft guidance for public consultation which recommends sapropterin (Kuvan, BioMarin) for treating phenylketonuria ...
Posted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 17 Feb 2021
Lupin responds to NICE Appraisal Consultation Document on NaMuscla (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders
16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) ...
Posted by Michael Wonder on 17 Feb 2021
bluebird bio ‘baffled’ after NICE rejects beta thalassaemia gene therapy
16 February 2021 - It’s back to the drawing board for bluebird bio and its discussions with NICE, which has ...
Posted by Michael Wonder on 15 Feb 2021
NICE rejects Lilly’s Verzenios for advanced breast cancer
15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of ...
Posted by Michael Wonder on 15 Feb 2021
bluebird bio’s beta thalassaemia gene therapy rejected by NICE
12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s ...
Posted by Michael Wonder on 14 Feb 2021
Skin cancer drug recommended for routine NHS use
12 February 2021 - An appeal period has now opened until 26 February 2021. ...
Posted by Michael Wonder on 04 Feb 2021
Thousands of lung cancer patients to benefit from life extending treatment
4 February 2021 - A potentially life extending treatment for some people with non-squamous, non-small-cell lung cancer will now be available ...
Posted by Michael Wonder on 27 Jan 2021
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
27 January 2021 - Bristol Myers Squibb’s Revlimid (lenalidomide) has received a recommendation from the UK’s NICE for newly diagnosed ...
Posted by Michael Wonder on 22 Jan 2021
NICE recommends Jyseleca (filgotinib) on NHS in landmark decision for rheumatoid arthritis
21 January 2021 - NICE guidance, for the first time in the UK, supports access to an advanced therapy for people ...
Posted by Michael Wonder on 21 Jan 2021
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
21 January 2021 - NICE has published its final appraisal determination recommending the use of Gilead Sciences and Galapagos’ Jyseleca ...
Posted by Michael Wonder on 20 Jan 2021
Amryt’s Myalepta scores NICE backing for rare lipid disorder
20 January 2021 - NICE has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS. ...